Clinical Trials Sponsored by Fujian Cancer Hospital

Total 10554 results

Fujian Cancer Hospital
First Affiliated Hospital of Fujian Medical University; Fujian Provincial Hospital and other collaborators

Not yet recruiting

MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer

Endometrial Neoplasms

China
Fujian Cancer Hospital
Fujian Provincial Hospital

Not yet recruiting

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Ovarian Neoplasms
Fujian Cancer Hospital

Not yet recruiting

A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer

Mid-low Rectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury

Rectal Diseases | Radiation Injuries
Fujian Cancer Hospital

Not yet recruiting

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Colo-rectal Cancer
Fujian Cancer Hospital

Not yet recruiting

MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

MRI | Cervical Cancer | Radiotherapy | Prognostic Model

China
Fujian Cancer Hospital

Not yet recruiting

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Gastric Cancer
Fujian Cancer Hospital

Not yet recruiting

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Cervical Cancer
Fujian Cancer Hospital

Not yet recruiting

A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy

Cervical Cancer | Radiotherapy | Risk Factor | Prognostic Model | Distant Metastasis

China
Fujian Cancer Hospital

Not yet recruiting

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer

Cervix Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

Gastrointestinal Tumors
Fujian Cancer Hospital

Not yet recruiting

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Lung Adenocarcinoma | PD-1 Inhibitor | Stage IV Non-small Cell Lung Cancer | VEGF
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
Fujian Cancer Hospital

Recruiting

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Digestive System Neoplasms | Esophageal Neoplasms | Esophageal Diseases

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapy Effect | Angiogenesis
Fujian Cancer Hospital

Not yet recruiting

Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain

Hawthorn Red Combined Refractory Cancer Pain
Fujian Cancer Hospital

Not yet recruiting

To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Colon Cancer
Fujian Cancer Hospital

Recruiting

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Gastric Cancer Stage IV

China
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy | Gastrict Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Effects of Mobile Medicine on Cancer Patients

Cancer Pain
Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Fujian Cancer Hospital

Active, not recruiting

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). (ERI-Based-01)

Breast Cancer

China
Fujian Cancer Hospital

Completed

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

Cancer Pain

China
Fujian Cancer Hospital

Withdrawn

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer (SIRB2)

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Unknown

Study of the Combination of Apatinib and POF

Gastric Adenocarcinoma

China
Fujian Cancer Hospital

Unknown

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Non-squamous Non-small Cell Lung Cancer
Fujian Cancer Hospital

Unknown

Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer

Radiation Induced Oral Mucositis

China
Fujian Cancer Hospital

Unknown

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (Geber)

Lung Adenocarcinoma | EGFR Mutation

China
Fujian Cancer Hospital

Unknown

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Chemotherapy Effect | NSCLC Stage IV

China
Fujian Cancer Hospital

Unknown

Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment

SCLC
Fujian Cancer Hospital

Unknown

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Advanced Gastric Cancer

China
Fujian Cancer Hospital

Unknown

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Fujian Cancer Hospital

Unknown

Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer

Locally Advanced Gastric Cancer | Total Laparoscopic Distal Gastrectomy
Fujian Cancer Hospital

Not yet recruiting

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma | Intermittent Systematic Chemotherapy
Fujian Cancer Hospital

Not yet recruiting

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

EGFR Positive Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Recruiting

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Untreated Advanced Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Not yet recruiting

New-mode Clinical Target Volume Delineation of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma by AJCC V8 Stage
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Fujian Cancer Hospital

Not yet recruiting

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital

Recruiting

HRQOL in Locally Advanced Thyroid Carcinoma (LATCQOL)

Thyroid Cancer | Health Related Quality of Life | Tyrosine Kinase Inhibitor

China
Fujian Cancer Hospital

Recruiting

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Ovarian Diseases | Ovarian Neoplasms

China
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy Gastrict Cancer

China
Fujian Cancer Hospital

Not yet recruiting

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Solid Tumors
Fujian Cancer Hospital

Not yet recruiting

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Rectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Ovarian Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Immunotherapy

3

Subscribe